Oncology Resource Center

Register for your FREE account now and join the thousands of healthcare professionals who have depended on us for over 26 years for accurate, concise, and timely drug information.

Email*

Password*

Keep me logged in Forgot your password?

Email*

Oncology Resource Center

Welcome to the MPR Oncology Resource Center, where you will find everything you need to make informed clinical decisions.

Drug Monographs

Click on the subcategory below to find drug monographs for that particular area.

News

ATS: Benefits/Harms of Low-Dose CT Screening Assessed

Although low-dose computed tomography (LDCT) screening may be beneficial for some individuals, there are concerns about the potential harms of screening.

Dabrafenib Safe, Active Against Some Metastatic Melanomas

Dabrafenib, the mutant BRAF-selective inhibitor of BRAF kinase, is safe for treating solid tumors and shows antitumor activity against Val600-mutant BRAF melanomas and other solid tumors, including melanomas that have metastasized to the brain.

DDW: Flexible Sigmoidoscopy Tied to Lower CRC Incidence

Screening with flexible sigmoidoscopy correlates with significant reductions in the incidence of distal and proximal colorectal cancer and in distal colorectal cancer mortality.

US Task Force Recommends Against PSA-Based Screening

The US Preventive Services Task Force (USPSTF) recommends against the use of the prostate-specific antigen (PSA)-based screening for men in the general US population.

ATS: Sleep Apnea Tied to Increased Risk of Cancer Death

Obstructive sleep apnea (OSA) is associated with an increased risk of cancer mortality.

VORAXAZE

5/7/2012

BTG International

Pharmacological Class: Carboxypeptidase enzyme.

Active Ingredient(s): Glucarpidase; 1,000 Units/vial; lyophilized powder for IV injection after reconstitution; preservative-free.

Indication: Treatment of toxic plasma methotrexate (MTX) concentrations (>1 micromole per liter) in patients with delayed MTX clearance due to impaired renal function.

INLYTA

3/26/2012

Pfizer Inc.

Pharmacological Class: Kinase inhibitor.

Active Ingredient(s): Axitinib 1mg, 5mg; tabs.

Indication: Treatment of advanced renal cell carcinoma (RCC) after failure of one prior systemic therapy.

ERIVEDGE

3/19/2012

Genentech, Inc.

Pharmacological Class: Hedgehog pathway inhibitor.

Active Ingredient(s): Vismodegib 150mg; caps.

Indication: Treatment of adults with metastatic basal cell carcinoma, or locally advanced basal cell carcinoma that has recurred following surgery or who are not candidates for surgery, and who are not candidates for radiation.